ADC Therapeutics SA Current Ratio 2019-2022 | ADCT

ADC Therapeutics SA current ratio from 2019 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
ADC Therapeutics SA Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.44B $0.09B 5.00
2022-06-30 $0.42B $0.07B 5.76
2022-03-31 $0.49B $0.07B 6.89
2021-12-31 $0.53B $0.07B 7.10
2021-09-30 $0.57B $0.06B 9.59
2021-06-30 $0.39B $0.05B 7.66
2021-03-31 $0.39B $0.04B 9.50
2020-12-31 $0.45B $0.04B 11.14
2020-09-30 $0.51B $0.03B 15.55
2020-06-30 $0.36B $0.03B 11.45
2020-03-31 $0.00B 0.00
2019-12-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
2019-06-30 $0.00B 0.00
2018-12-31 $0.14B $0.02B 6.36
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.388B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.040B 9.40
GSK (GSK) United Kingdom $72.263B 9.00
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.195B 19.11
Ginkgo Bioworks Holdings (DNA) United States $3.764B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.675B 25.14
Biohaven (BHVN) United States $1.282B 0.00
Emergent Biosolutions (EBS) United States $0.672B 5.28
Ambrx Biopharma (AMAM) United States $0.075B 0.00
Enzo Biochem (ENZ) United States $0.069B 0.00
Gelesis Holdings (GLS) United States $0.026B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00